231 related articles for article (PubMed ID: 21189378)
1. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.
Klümpen HJ; Queiroz KC; Spek CA; van Noesel CJ; Brink HC; de Leng WW; de Wilde RF; Mathus-Vliegen EM; Offerhaus GJ; Alleman MA; Westermann AM; Richel DJ
J Clin Oncol; 2011 Feb; 29(6):e150-3. PubMed ID: 21189378
[No Abstract] [Full Text] [Related]
2. Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned.
de Brabander J; Eskens FALM; Korsse SE; Dekker E; Dewint P; van Leerdam ME; van Eeden S; Klümpen HJ
Oncologist; 2018 Apr; 23(4):399-e33. PubMed ID: 29371475
[TBL] [Abstract][Full Text] [Related]
3. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Liakakos T; Roukos DH
Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
[No Abstract] [Full Text] [Related]
4. Promising advances in the treatment of malignant pancreatic endocrine tumors.
Jensen RT; Delle Fave G
N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
[No Abstract] [Full Text] [Related]
5. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model.
Wei C; Amos CI; Zhang N; Zhu J; Wang X; Frazier ML
Cancer Lett; 2009 May; 277(2):149-54. PubMed ID: 19147279
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.
Resta N; Pierannunzio D; Lenato GM; Stella A; Capocaccia R; Bagnulo R; Lastella P; Susca FC; Bozzao C; Loconte DC; Sabbà C; Urso E; Sala P; Fornasarig M; Grammatico P; Piepoli A; Host C; Turchetti D; Viel A; Memo L; Giunti L; Stigliano V; Varesco L; Bertario L; Genuardi M; Lucci Cordisco E; Tibiletti MG; Di Gregorio C; Andriulli A; Ponz de Leon M;
Dig Liver Dis; 2013 Jul; 45(7):606-11. PubMed ID: 23415580
[TBL] [Abstract][Full Text] [Related]
7. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.
Hearle N; Schumacher V; Menko FH; Olschwang S; Boardman LA; Gille JJ; Keller JJ; Westerman AM; Scott RJ; Lim W; Trimbath JD; Giardiello FM; Gruber SB; Offerhaus GJ; de Rooij FW; Wilson JH; Hansmann A; Möslein G; Royer-Pokora B; Vogel T; Phillips RK; Spigelman AD; Houlston RS
Clin Cancer Res; 2006 May; 12(10):3209-15. PubMed ID: 16707622
[TBL] [Abstract][Full Text] [Related]
8. Treatment: symptomatic treatment of hypoglycaemia.
Tabarin A; Goichot B;
Ann Endocrinol (Paris); 2013 Jul; 74(3):196-9. PubMed ID: 23791453
[No Abstract] [Full Text] [Related]
9. Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.
Carbonnaux M; Molin Y; Souquet PJ; Tantin A; Lombard-Bohas C; Walter T
Invest New Drugs; 2014 Dec; 32(6):1308-10. PubMed ID: 25119297
[TBL] [Abstract][Full Text] [Related]
10. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.
Kuwada SK; Burt R
Fam Cancer; 2011 Sep; 10(3):469-72. PubMed ID: 21826537
[TBL] [Abstract][Full Text] [Related]
11. Are we missing the mTOR target in breast cancer?
Johnston SR
Breast Cancer Res Treat; 2011 Aug; 128(3):607-11. PubMed ID: 20953834
[No Abstract] [Full Text] [Related]
12. Everolimus for the treatment of pancreatic neuroendocrine tumors.
Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
[TBL] [Abstract][Full Text] [Related]
13. Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation.
Schrader J; Henes FO; Perez D; Burdak-Rothkamm S; Stein A; Izbicki JR; Lohse AW
Ann Oncol; 2017 Apr; 28(4):904-905. PubMed ID: 28327903
[No Abstract] [Full Text] [Related]
14. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
15. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
16. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
17. [mTOR inhibitors, autophagia and Cancer: looking forward to a universal financial coverage].
Arancibia J; Labbé TP; Ríos JA
Rev Med Chil; 2019 May; 147(5):674-676. PubMed ID: 31859903
[No Abstract] [Full Text] [Related]
18. STK11 genotyping and cancer risk in Peutz-Jeghers syndrome.
Schumacher V; Vogel T; Leube B; Driemel C; Goecke T; Möslein G; Royer-Pokora B
J Med Genet; 2005 May; 42(5):428-35. PubMed ID: 15863673
[No Abstract] [Full Text] [Related]
19. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.
Su GH; Hruban RH; Bansal RK; Bova GS; Tang DJ; Shekher MC; Westerman AM; Entius MM; Goggins M; Yeo CJ; Kern SE
Am J Pathol; 1999 Jun; 154(6):1835-40. PubMed ID: 10362809
[TBL] [Abstract][Full Text] [Related]
20. [Hyperglycaemia during treatment with everolimus].
Opdam FL; Huitema AD; Beijnen JH; Schellens JH
Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
